Brief: Pfizer Says Talzenna Plus Xtandi Improves Radiographic Progression-Free Survival By Over 50% In Metastatic Prostate Cancer
30/05/2026 13:06
BRIEF-Pfizer Says Talzenna Plus Xtandi Improves Radiographic Progression-Free Survival By Over 50% In Metastatic Prostate Cancer May 30 (Reuters) - Pfizer Inc PFE.N:
PFIZER - TALZENNA PLUS XTANDI IMPROVES RADIOGRAPHIC PROGRESSION-FREE SURVIVAL BY OVER 50% IN METASTATIC PROSTATE CANCER
Source text: ID:nBw2wYdJ5a
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials